FMWA
STRO icon

Forvis Mazars Wealth Advisors’s Sutro Biopharma STRO Stock Holding History

Forvis Mazars Wealth Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,284
Closed -$23.6K – 426
2024
Q4 		$23.6K Hold
1,284
– – ﹤0.01% 419
2024
Q3 		$44.4K Hold
1,284
– – ﹤0.01% 428
2024
Q2 		$37.6K Buy
+1,284
New +$50.8K ﹤0.01% 399

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Forvis Mazars Wealth Advisors's STRO Position: Q1 2025 in Review

Forvis Mazars Wealth Advisors sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 1,284 shares — an estimated $23.6K sold.

Forvis Mazars Wealth Advisors first reported a position in STRO in Q2 2024 and held it in 3 quarters. The position peaked at $44.4K in Q3 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Forvis Mazars Wealth Advisors reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Forvis Mazars Wealth Advisors sold 1,284 Sutro Biopharma shares in Q1 2025, an estimated $23.6K.
  • Forvis Mazars Wealth Advisors first reported a position in Sutro Biopharma in Q2 2024 and held it in 3 quarters.
  • Forvis Mazars Wealth Advisors's Sutro Biopharma position peaked at $44.4K in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q1 2025, filed 13 May 2025.